Clinical Trials Logo

Solid Tumors clinical trials

View clinical trials related to Solid Tumors.

Filter by:

NCT ID: NCT03965845 Completed - Solid Tumors Clinical Trials

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Start date: June 25, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor telaglenestat (CB-839) with the CDK4/6 Inhibitor, palbociclib in participants with advanced/metastatic solid tumors.

NCT ID: NCT03946800 Completed - Cancer Clinical Trials

A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

Start date: May 8, 2019
Phase: Phase 1
Study type: Interventional

To evaluate MEDI1191 administered intratumorally in sequential and concurrent combination with intravenous durvalumab in patients with solid tumors.

NCT ID: NCT03762447 Completed - Solid Tumors Clinical Trials

A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors

Start date: December 10, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB086550 in participants with advanced solid tumors who have failed prior treatments.

NCT ID: NCT03745989 Completed - Solid Tumors Clinical Trials

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

Start date: February 22, 2019
Phase: Phase 1
Study type: Interventional

This is a multicenter, worldwide, open-label study of MK-8353 in combination with selumetinib in participants with histologically or cytologically confirmed diagnosis of advanced solid tumor. This study will evaluate the safety, tolerability, and exploratory efficacy of MK-8353 in combination with selumetinib.

NCT ID: NCT03724890 Completed - Solid Tumors Clinical Trials

Study of Avelumab-M3814 Combinations

Start date: November 27, 2018
Phase: Phase 1
Study type: Interventional

The main purpose of the study is to evaluate a safe, tolerable recommended Phase II dose (RP2D) and/or the maximum tolerated dose (MTD) of M3814 when given in combination with avelumab with and without radiotherapy in participants with selected advanced solid tumors.

NCT ID: NCT03641586 Completed - Solid Tumors Clinical Trials

The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor

Start date: October 12, 2015
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability, pharmacokinetics, food effect, and preliminary antitumor activities of BGB-283 in Chinese subjects with local advanced or metastatic malignant solid tumor.

NCT ID: NCT03616834 Completed - Solid Tumors Clinical Trials

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

Start date: July 25, 2018
Phase: Phase 2
Study type: Interventional

Phase 2, open-label study that will evaluate the safety, tolerability, antitumor activities.

NCT ID: NCT03477175 Completed - Solid Tumors Clinical Trials

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

Start date: August 16, 2018
Phase: Phase 2
Study type: Interventional

This study will be conducted to assess the long-term safety of study drug(s) in participants who are enrolled in Eisai-sponsored lenvatinib studies.

NCT ID: NCT03473925 Completed - Clinical trials for Non-small Cell Lung Cancer

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Start date: April 10, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive refractory non-small cell lung cancer (NSCLC), castration resistant prostate cancer (CRPC) or microsatellite stable (MSS) colorectal cancer (CRC).

NCT ID: NCT03386942 Completed - Solid Tumors Clinical Trials

A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors

Start date: November 28, 2017
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the tolerability and safety profile of farletuzumab ecteribulin in participants with solid tumors.